LORVIQUA

(lorlatinib)

Find LORVIQUA medical information:

Find LORVIQUA medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

LORVIQUA Quick Finder

    The Summary of Product Characteristics (SPC) for Lorviqua, film-coated tablets (25mg or 100mg) is available here. 

    Lorviqua (lorlatinib) as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.

    Lorviqua as monotherapy is indicated for the treatment of adult patients with ALK-positive advanced NSCLC whose disease has progressed after:

    • alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or
    • crizotinib and at least one other ALK TKI.

    Didn’t find what you were looking for? 

    Contact us

    Call 01 58 07 34 40*

    *Contact Medical Information. 09h - 18h Monday to Friday.

    Medical Inquiry

    Submit a medical question for Pfizer prescription products.

    Report Adverse Event

    Pfizer Safety 

    To report an adverse event related to the Pfizer-BioNTech COVID-19 vaccines, click the link below:
    www.pfizersafetyreporting.com
    If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please contact Pfizer pharmacovigilance at [email protected].

    Governmental website 

    You may also report adverse events online on the Ministry of Health’s website ‘Portail de signalement des événements sanitaires indésirables’ at https://signalement.social-sante.gouv.fr